← Eichor
Condition: Metastatic Her2 Negative Breast Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Metastatic Her2 Negative Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · 590 location(s) · SWOG Cancer Research Network · NCT03418961Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Phase 1/Phase 2 · 22 location(s) · Forward Pharmaceuticals Co., Ltd. · NCT06064812Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
EARLY_Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06828588Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Phase 2 · 1 location(s) · The Methodist Hospital Research Institute · NCT05305924Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastat
Phase 1/Phase 2 · 2 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT06167694RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07065435A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurr
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07520760Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Phase 1/Phase 2 · 12 location(s) · Artios Pharma Ltd · NCT05898399Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Canc
Phase 2 · 1 location(s) · RemeGen Co., Ltd. · NCT06642545Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07630961A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT04683679Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06839560DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
Phase N/A · 1 location(s) · Mayo Clinic · NCT06388122Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
Phase 2 · 2 location(s) · Fudan University · NCT07471776Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Br
Phase 1/Phase 2 · 3 location(s) · Washington University School of Medicine · NCT06374459Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Phase 2 · 9 location(s) · Institut Curie · NCT07193394Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors,
Phase N/A · 1 location(s) · Hunan Cancer Hospital · NCT07073755Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/
Phase 1/Phase 2 · 14 location(s) · Ellipses Pharma · NCT05573126ctDNA-guided Treatment Decision-making
Phase 2 · 1 location(s) · Fudan University · NCT07394218Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06649331Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Phase 2 · 1 location(s) · Brown University · NCT06974604PRE-I-SPY Phase I/Ib Oncology Platform Program
Phase 1 · 7 location(s) · QuantumLeap Healthcare Collaborative · NCT05868226A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestran
Phase 1/Phase 2 · 52 location(s) · Genentech, Inc. · NCT07100106A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Phase 1/Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06110793First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tu
Phase 1 · 37 location(s) · Relay Therapeutics, Inc. · NCT05216432Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or
Phase 3 · 88 location(s) · Daiichi Sankyo · NCT05950945Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Phase 1 · 8 location(s) · Olema Pharmaceuticals, Inc. · NCT06784193A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Phase 2 · 13 location(s) · Processa Pharmaceuticals · NCT06568692The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT05075512
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.